Business
Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights
- Recent biomarker data identifies a simple blood test that may predict clinical respons...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights- Recent biomarker data identifies a simple blood test that may predict clinical response to pelareorep -- AWARE-1 window of opportunity study in breast cancer to begin enrollment in the coming weeks with data expected in the second half of 2019 -- Combination studies with checkpoint inhibitors are evaluating biomarker data and support progression into registration pathway for metastatic breast cancer -- Management to host webcast and conference call today at 8:30 a.m. ET -CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / March 8, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter and year ended December 31, 2018. All dollar amounts are expressed in Canadian currency unless otherwise noted.''With a growing number of large pharma collaborations, continued advancement with our registration program in metastatic breast cancer and recently announced biomarker data, we have made tremendous progress in a short period of time,'' said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. ''In 2019 we expect to generate data that will allow us to finalize our registration program in breast cancer, while at the same time advancing studies in indications with prior evidence of clinical activity, as defined by an inflamed phenotype. With the global market for checkpoint inhibitors expected to reach $25 billion in 2022 and checkpoint inhibitors only able to treat approximately twenty percent of patients, the data demonstrating pelareorep's ability to create an inflamed phenotype and boost PD-L1 expression makes it a potential backbone for this drug class. Furthermore, we believe pelareorep can potentially expand the utility of checkpoint inhibitors into additional indications and this work is already underway with Merck's Keytruda in both multiple myeloma and pancreatic cancer, Bristol-Myers Squibb's Opdivo in multiple myeloma and Roche's Tecentriq in breast cancer.''Selected highlights since January 1, 2018Clinical & Scientific Updates Received confirmation from the FDA and EMA that only a single phase 3 study is required for approval Granted a Special Protocol Assessment (SPA) from ...